Pharmacovigilance and risk management are key activities for ensuring that the right products get to patients at the right time with the right balance of benefits and risks. Optimizing benefit-risk is an important matter not just for regulators, but for all stakeholders, and planning for pharmacovigilance activities and appropriate evidence gathering must be done throughout the medicine life cycle. Against a backdrop of rapid therapeutic innovation, technologic advances, and widening choices of potential safety data sources and analytical methodologies, the pharmacovigilance and risk management of today demand ever smarter approaches.
DIA’s Pharmacovigilance and Risk Management Strategies Conference is the leading forum for exploring insights into new technologies and innovative methods and how they can be utilized for pharmacovigilance in the broadest sense. The 2017 program will focus on cutting edge innovation across the entire life cycle of biopharmaceutical products – new therapeutic approaches to diseases that change patients’ lives, enlightened evolution of regulatory science that speeds needed products to prescribers and patients, and, most importantly, engagement of patients in the product development and regulatory processes. This valuable forum brings together industry, academia, regulators, and patient representatives for thought provoking sessions and candid discussion of common challenges.